Bristol Myers Squibb to present oncology data at ESMO 2026

Bristol Myers Squibb will present 12 oral presentations and nearly 60 disclosures at ESMO 2026 in Madrid. Late-breaking Phase 3 data for iza-bren will be presented for EGFR-mutated NSCLC and HR+/HER2- breast cancer. Global Phase 2 data for pumitamig, a PD-L1 × VEGF-A bispecific immunomodulator, is scheduled for rapid oral presentation. Long-term survival results for Opdivo plus Yervoy combination therapy will be featured in a Phase 3 oral session.

BMS RayzeBio RYZ101 meets primary endpoint in ACTION-1 trial

RYZ101 met primary endpoint for progression-free survival in ACTION-1 trial. Study targeted SSTR+ GEP-NETs patients progressing after Lu177 therapy. First Phase 3 results for alpha-isotope based targeted radiopharmaceutical. FDA granted Orphan Drug Designation for RYZ101 in August 2026.

Bristol Myers Squibb's Zenbexus cuts blood cancer progression risk by 51%

Zenbexus combination reduced disease progression or death risk by 51%. Median progression-free survival reached 42 months vs 20 months for standard care. FDA granted accelerated approval to Zenbexus in August as first CELMoD. Study involved 800 patients with first relapse of multiple myeloma.

FDA approves Camzyos for pediatric and adult oHCM patients

FDA approves Camzyos (mavacamten) for adults and pediatric patients weighing 30 kg or more with symptomatic oHCM, making it the only FDA-approved therapy for oHCM in a pediatric population. Approval based on Phase 3 SCOUT-HCM trial, where Camzyos achieved a statistically significant reduction in Valsalva LVOT gradient at Week 28 vs placebo (LS Mean Difference: −48.0 mm Hg; P<0.0001). No patients in SCOUT-HCM experienced LVEF below 50% and no adverse events led to treatment discontinuation; serious adverse events occurred in 9% (Camzyos) vs 10% (placebo). Camzyos now holds the broadest indication of any cardiac myosin inhibitor and has been prescribed by more than 5,000 healthcare providers to over 25,000 patients in the US. Pediatric data is being discussed with multiple global regulatory authorities for potential pediatric indications.

BMS ZENBEXUS doubles MRD-negative response rates in Phase 3 myeloma trial

ZENBEXUS combination achieved 41.1% MRD-negative complete response rate vs 20.7% for standard therapy. Overall response rate reached 88.9% with ZENBEXUS triplet compared to 76.1% for comparator. Grade 3/4 neutropenia occurred in 84.3% of ZENBEXUS patients but was manageable with support. Peripheral neuropathy rates were markedly lower with ZENBEXUS (12.3%) than comparator (42.6%).

Bristol Myers Squibb to report Q3FY26 results on Oct 29

Bristol Myers Squibb to report Q3 2026 results on October 29, 2026. Conference call scheduled for 8:00 a.m. ET with executive participation. Live webcast and replay available via investor relations website.